These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

864 related items for PubMed ID: 24099077

  • 1. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
    [Abstract] [Full Text] [Related]

  • 2. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    J Clin Oncol; 2013 Nov 01; 31(31):3997-4013. PubMed ID: 24101045
    [Abstract] [Full Text] [Related]

  • 3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists.
    Arch Pathol Lab Med; 2007 Nov 01; 131(1):18-43. PubMed ID: 19548375
    [Abstract] [Full Text] [Related]

  • 4. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr 01; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 5. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.
    Arch Pathol Lab Med; 2018 Nov 01; 142(11):1364-1382. PubMed ID: 29846104
    [Abstract] [Full Text] [Related]

  • 6. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    J Clin Oncol; 2007 Jan 01; 25(1):118-45. PubMed ID: 17159189
    [Abstract] [Full Text] [Related]

  • 7. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar 01; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 8. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun 01; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 9. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.
    J Clin Oncol; 2018 Jul 10; 36(20):2105-2122. PubMed ID: 29846122
    [Abstract] [Full Text] [Related]

  • 10. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM.
    Virchows Arch; 2016 Feb 10; 468(2):207-11. PubMed ID: 26521061
    [Abstract] [Full Text] [Related]

  • 11. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P.
    Arch Pathol Lab Med; 2014 Feb 10; 138(2):213-9. PubMed ID: 24164555
    [Abstract] [Full Text] [Related]

  • 12. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH, Wang K, Lin DY, Xu J, Chen J, Long XY, Ge Y, Luo XL, Zhang KP, Liu YH, Xu FP.
    Breast Cancer Res Treat; 2019 May 10; 175(1):51-57. PubMed ID: 30712197
    [Abstract] [Full Text] [Related]

  • 13. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 10; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0).
    Wilcock D, Sirohi D, Albertson D, Cleary AS, Coleman JF, Jedrzkiewicz J, Mahlow J, Ruano AL, Gulbahce HE.
    Arch Pathol Lab Med; 2024 Aug 01; 148(8):890-897. PubMed ID: 37934954
    [Abstract] [Full Text] [Related]

  • 15. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.
    Hum Pathol; 2010 Jan 01; 41(1):103-6. PubMed ID: 19762065
    [Abstract] [Full Text] [Related]

  • 16. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Shanmugalingam A, Hitos K, Pathmanathan N, Edirimmane S, Hughes TM, Ngui NK.
    Breast Cancer Res Treat; 2023 Feb 01; 198(1):143-148. PubMed ID: 36604351
    [Abstract] [Full Text] [Related]

  • 17. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0.
    Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Arch Pathol Lab Med; 2020 May 01; 144(5):597-601. PubMed ID: 31647316
    [Abstract] [Full Text] [Related]

  • 18. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Liu Y, Wu S, Shi X, Luo Y, Pang J, Wang C, Mao F, Liang Z, Zeng X.
    Breast Cancer Res Treat; 2019 Nov 01; 178(2):275-281. PubMed ID: 31388934
    [Abstract] [Full Text] [Related]

  • 19. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
    Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH.
    J Clin Oncol; 2023 Aug 01; 41(22):3867-3872. PubMed ID: 37284804
    [Abstract] [Full Text] [Related]

  • 20. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B, Ding W, Sun K, Wang X, Xu L, Teng X.
    Sci Rep; 2019 Nov 13; 9(1):16726. PubMed ID: 31723206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.